Sotera Health (NASDAQ:SHC) Receives Average Rating of “Moderate Buy” from Brokerages

Sotera Health (NASDAQ:SHC) has earned an average recommendation of “Moderate Buy” from the six ratings firms that are presently covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $16.92.

A number of research analysts recently issued reports on the stock. Barclays decreased their price objective on shares of Sotera Health from $19.00 to $14.00 and set an “overweight” rating for the company in a report on Wednesday, April 10th. Citigroup raised shares of Sotera Health from a “neutral” rating to a “buy” rating and lowered their target price for the stock from $18.00 to $16.00 in a report on Wednesday, April 3rd. TheStreet raised Sotera Health from a “d” rating to a “c-” rating in a report on Tuesday, February 27th. Jefferies Financial Group upgraded shares of Sotera Health from a “hold” rating to a “buy” rating and lifted their target price for the stock from $15.00 to $15.50 in a research report on Monday, March 25th. Finally, Piper Sandler began coverage on Sotera Health in a research report on Tuesday, May 21st. They issued a “neutral” rating and a $13.00 price objective for the company.

Sotera Health Stock Down 0.9 %

NASDAQ SHC opened at $11.59 on Monday. Sotera Health has a twelve month low of $10.71 and a twelve month high of $19.40. The company has a debt-to-equity ratio of 5.39, a quick ratio of 2.86 and a current ratio of 3.20. The firm has a 50-day simple moving average of $11.35 and a 200 day simple moving average of $13.62. The stock has a market cap of $3.28 billion, a PE ratio of 61.00 and a beta of 2.05.

Sotera Health (NASDAQ:SHC) last posted its quarterly earnings data on Thursday, May 2nd. The company reported $0.11 EPS for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.01). Sotera Health had a return on equity of 48.47% and a net margin of 5.09%. The business had revenue of $248.18 million during the quarter, compared to analyst estimates of $254.73 million. On average, research analysts forecast that Sotera Health will post 0.63 EPS for the current year.

Institutional Investors Weigh In On Sotera Health

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Janus Henderson Group PLC raised its position in shares of Sotera Health by 43.6% in the first quarter. Janus Henderson Group PLC now owns 14,892,868 shares of the company’s stock worth $178,865,000 after buying an additional 4,525,056 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Sotera Health by 27.0% in the first quarter. Vanguard Group Inc. now owns 12,145,110 shares of the company’s stock worth $145,863,000 after purchasing an additional 2,579,248 shares during the last quarter. Khrom Capital Management LLC bought a new stake in Sotera Health in the first quarter valued at $14,626,000. Irenic Capital Management LP raised its stake in Sotera Health by 103.2% in the fourth quarter. Irenic Capital Management LP now owns 2,233,195 shares of the company’s stock worth $37,629,000 after buying an additional 1,134,039 shares in the last quarter. Finally, Norges Bank bought a new stake in shares of Sotera Health during the fourth quarter valued at approximately $16,432,000. 91.03% of the stock is currently owned by institutional investors.

Sotera Health Company Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.